Last Updated : January 7, 2025
Details
FilesGeneric Name:
delgocitinib
Project Status:
Received
Therapeutic Area:
Chronic hand eczema
Manufacturer:
LEO Pharma Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0875-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of moderate to severe chronic hand eczema (CHE), including
the relief of pain and pruritus, in adults who have had an inadequate response
to, or for whom topical corticosteroids are not advisable.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the treatment of moderate to severe chronic hand eczema (CHE), including
the relief of pain and pruritus, in adults who have had an inadequate response
to, or for whom topical corticosteroids are not advisable.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 19-Sep-24 |
|---|---|
| Call for patient/clinician input closed | 12-Nov-24 |
| Submission received | 25-Nov-24 |
| Submission accepted | - |
| Clarification: - Submission was not accepted for review on 09 Dec 2024 | |
Files
Last Updated : January 7, 2025